2016 - Fellow of the Royal Society, United Kingdom
Fellow of The Academy of Medical Sciences, United Kingdom
Jack Cuzick mostly deals with Internal medicine, Gynecology, Breast cancer, Oncology and Tamoxifen. His study looks at the relationship between Internal medicine and fields such as Gastroenterology, as well as how they intersect with chemical problems. His Gynecology study incorporates themes from Cervical screening, Cervical intraepithelial neoplasia, Cervical cancer, Mass screening and Obstetrics.
Jack Cuzick has researched Breast cancer in several fields, including Odds ratio, Clinical trial, Surgery, Placebo and Risk factor. His Oncology research is multidisciplinary, relying on both Chemotherapy, Adjuvant therapy, Proportional hazards model, Selective estrogen receptor modulator and Endometrial cancer. His work carried out in the field of Tamoxifen brings together such families of science as Oncotype DX and Progesterone receptor.
His primary scientific interests are in Internal medicine, Breast cancer, Oncology, Gynecology and Tamoxifen. His Internal medicine study is mostly concerned with Cancer, Anastrozole, Prostate cancer, Clinical trial and Hazard ratio. His Breast cancer study integrates concerns from other disciplines, such as Odds ratio, Placebo, Randomized controlled trial and Risk factor.
The concepts of his Oncology study are interwoven with issues in Proportional hazards model, Estrogen receptor, Chemotherapy and Cohort. His study in Gynecology is interdisciplinary in nature, drawing from both Cervical cancer, Cervical intraepithelial neoplasia, Colposcopy, Cytology and Obstetrics. The various areas that Jack Cuzick examines in his Tamoxifen study include Aromatase and Adjuvant therapy.
His main research concerns Breast cancer, Internal medicine, Oncology, Cancer and Tamoxifen. His Breast cancer research incorporates elements of Proportional hazards model, Cohort and Obstetrics. He regularly links together related areas like MEDLINE in his Internal medicine studies.
His Oncology research incorporates themes from Framingham Risk Score, Chemotherapy, Recurrence score, Estrogen receptor and Stage. Jack Cuzick combines subjects such as Lower risk and Intensive care medicine with his study of Cancer. His work is dedicated to discovering how Tamoxifen, Gynecology are connected with Cytology and Mass screening and other disciplines.
His primary areas of investigation include Breast cancer, Internal medicine, Oncology, Gynecology and Obstetrics. His research integrates issues of Odds ratio and Case-control study in his study of Breast cancer. His biological study spans a wide range of topics, including Interquartile range, Chemotherapy, Predictive value of tests, Meta-analysis and Proportional hazards model.
His Gynecology study incorporates themes from Cervical screening, Colposcopy, Vaccination and Mass screening. The concepts of his Obstetrics study are interwoven with issues in Breast imaging, Cervical intraepithelial neoplasia, Disease and Human papillomavirus. The Anastrozole study combines topics in areas such as Randomized controlled trial and Oncotype DX Breast Cancer Assay.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
E. E. Calle;C. W. Heath;R. J. Coates;J. M. Liff.
The Lancet (1997)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
M Baum;A U Budzar;J Cuzick;J Forbes.
The Lancet (2002)
Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial
Wendy S. Atkin;Rob Edwards;Ines Kralj-Hans;Kate Wooldrage.
The Lancet (2010)
Breast cancer and hormonal contraceptives : collaborative reanalysis of individual data on 53.297 women with breast cancer and 100.239 women without breast cancer from 54 epidemiological studies
E. E. Calle;C. W. Heath;H. L. Miracle-McMahill;R. J. Coates.
The Lancet (1996)
A wilcoxon-type test for trend
Statistics in Medicine (1985)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett;Torsten O. Nielsen;Roger A’Hern;John Bartlett.
Journal of the National Cancer Institute (2011)
Long-term risk of colorectal cancer after excision of rectosigmoid adenomas
Wendy S. Atkin;Basil C. Morson;Jack Cuzick.
The New England Journal of Medicine (1992)
Overview of the European and North American studies on HPV testing in primary cervical cancer screening.
Jack Cuzick;Christine Clavel;Karl Ulrich Petry;Chris J L M Meijer.
International Journal of Cancer (2006)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick;Ivana Sestak;Michael Baum;Aman U Buzdar.
Lancet Oncology (2010)
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group.
IC Henderson;H Mouridsen;O Abe;M Abeloff.
The New England Journal of Medicine (1988)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: